Search
forLearn
5 / 801 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Overview
learn EUK 134
learn Beta Polypeptide
Research
5 / 1000+ resultsresearch Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry—The European and North America Regulation Challenges
Nanocarriers can enhance cosmetics but face regulatory and safety challenges.
research Procedure of Tattooing
Tattooing guidelines focus on safety, hygiene, and following rules.
research Causal links between 13 autoimmune diseases and graft dysfunction: A Mendelian randomization study
Alopecia areata may protect against graft dysfunction, while asthma may increase its risk.
research The genetic link between thyroid dysfunction and alopecia areata: a bidirectional two-sample Mendelian randomization study
Thyroid issues can cause alopecia areata.
research Comparison of rheological properties, follicular penetration, drug release, and permeation behavior of a novel topical drug delivery system and a conventional cream
The new drug delivery system releases the drug better in sebum and targets follicles more effectively than the conventional cream.
Community Join
5 / 237 resultscommunity European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Heads up for EU Fin users: Finasteride prescription has been toughened up in France
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
community Brotzu lotion update
A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.